Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2010
Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. Coherus's mission is to improve patient lives by expanding access to these essential treatments, helping to offset rising healthcare costs. The company serves healthcare providers, hospitals, and patients, focusing on rigorous research and development to ensure their products meet high quality and efficacy standards. By providing cost-effective alternatives to original biologics, Coherus creates a competitive advantage in the biopharmaceutical market, driving sales and profitability while enhancing healthcare accessibility.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$950.7M
Above
Industry Average
Funded Over
7 Rounds
Competitive base salary
Target bonus based on performance
stock options
Medical, dental, & vision coverage
PTO
401(k) plan
FSA
STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZIĀ® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor
Coherus hired Sameer Goregaoker as senior VP of immuno-oncology marketing and Loqtorzi brand lead late last year.
Intech Investment Management LLC makes new $38,000 investment in Coherus BioSciences, Inc. (NASDAQ:CHRS).
Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference.
SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2010
Find jobs on Simplify and start your career today